The content on this site is intended for healthcare professionals only
Dr San Miguel speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the concept of complete response being a clear marker for predicting long term survival in myeloma.
He highlights the need for good, sensitive markers to discriminate between normal and malignant plasma cells.
He says that this could be an immunophenotypic marker based on a constellation of antigens that allow the distinction between malignant plasma cells and normal plasma cells.
Prostate cancer
Perspectives on advance care planning for advanced cancer in the Philippines
OncoAlert Round Up for September 15-21, 2023
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
Cancer Care in Older Adults and Special Population
Global adoption of single-shot targeted IORT for breast cancer
